CTM033
/ Lepu Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 28, 2022
Anti-CCR8 antibody CTM-033 inhibits tumor growth in vivo
(Bioworld)
- "Regulatory T cells (Tregs) are known suppressors of immunity activation in the tumor microenvironment, and a high density of Tregs is tied to a poor response to cancer immunotherapy, with CCR8+ Tregs identified as being highly suppressive. Ctm Bio Co. therefore have studied the CCR8 antagonist antibody CTM-033 in preclinical cancer models."
Preclinical • Oncology
1 to 1
Of
1
Go to page
1